ArticleBMC ophthalmology2025
Presumed reactivation of herpes simplex virus-associated endothelial keratitis after treatment with topical interferon-α 2b for ocular surface squamous neoplasia.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Topical and Systemic Therapeutic Approaches in the Treatment of Oral Herpes Simplex Virus Infection: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Topical Chemotherapy for Ocular Surface Squamous Neoplasia: A Review of Adverse Effects and Their Clinical Management.Oncology research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo report a case of herpes simplex virus (HSV)-associated endothelial keratitis in a patient receiving topical interferon (IFN)-α 2b for the management of ocular surface squamous neoplasia (OSSN). CASE PRESENTATION: A 65-year-old female was diagnosed with OSSN characterized by gelatinous growth on the left cornea, without conjunctival involvement. She had no history of herpetic keratitis. The patient was treated with topical IFN-α 2b 1 million IU/ml four times daily, leading to complete clinical resolution of the OSSN within three months. However, four months after initiating treatment, while still on the medication, she presented with decreased visual acuity, ocular injection, and pain in the left eye. Slit-lamp examination revealed central corneal stromal edema, infiltration, and keratic precipitates. A diagnosis of HSV endotheliitis was made, and IFN-α 2b was discontinued. The patient was treated with topical betamethasone 0.1% six times daily and oral acyclovir 400 mg five times daily, resulting in complete resolution of the disciform keratitis within three weeks. There has been no recurrence of herpetic infection or OSSN during 10 months of follow-up after discontinuing all medications.
conclusionOphthalmologists should be alert to the possibility of recurrent herpetic keratitis in patients treated with IFN-α 2b for OSSN who present with sudden visual decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.